

Relapsed/Refractory DLBCL: Patient-Provider Communication Checklist



Incidence and Common Symptoms


Diffuse large B-cell lymphoma (DLBCL) is among the most common subtypes of non-Hodgkin lymphoma; it often presents at a median age of 67 years¹

~194,000 new cases globally



15% and 37% of patients present with stage III and IV disease at diagnosis, respectively

Proportion of Cases by Stage¹



- Stage I (20%)**
Confined to Single Region
- Stage II (18%)**
Involving Multiple Regions
- Stage III (15%)**
Spread to Both Sides of Diaphragm
- Stage IV (37%)**
Diffuse or Disseminated Involvement
- Unknown (9%)**
Unstaged

At presentation, DLBCL may be associated with²⁻⁵:

- B symptoms (night sweats; weight loss; $\geq 37.5^{\circ}\text{C}$ fever or chills): ~30%
- Extranodal involvement: 40%
- Bone marrow involvement: 11%-34%
- Central nervous system involvement: 4.2%
 - ~2% of disease recurrence



Night sweats



Weight loss



Persistent fever even with no infection present

Current Therapy Options⁶

Initial Therapy

- Chemoimmunotherapy
- Radiation
- Clinical trial

Therapy at First Relapse (Relapsed/Refractory)

- Chemoimmunotherapy
- CAR T-cells
- Autologous stem cell transplant (ASCT)
- Clinical trial
- Antibody-drug conjugates (ADCs)
- Bispecific antibodies (BsAbs)

Therapy With 2 or More Relapses (Relapsed/Refractory)

- Alternative chemotherapy
- CAR T-cells
- ASCT
- Clinical trials
- BsAbs
- Pembrolizumab

Questions to Ask Your Doctor After a New Diagnosis or Relapsed/Refractory DLBCL

- Is DLBCL curable?
- Do I need to have any genetic/molecular testing done? How and when should this testing be done?
 - Do I have any relevant genetic abnormalities that might inform my prognosis?
- What are my treatment options and how do my genetic/molecular test results affect them?
 - What is chemoimmunotherapy?
 - Do I qualify for ASCT?
 - What is CAR T-cell therapy?
 - What are ADCs?
 - What are BsAbs?
- What types of side effects could I have with each of these treatment options?
- What is the expected treatment duration with the therapies I qualify for?
- Who will lead my treatment and how do I best communicate with them?
- Are there any resources for my family?

My Treatment

Treatment: Chemoimmunotherapy

Notes:



Possible side effects of therapy and when to call my care team

Notes:



Treatment: ASCT

Notes:



Possible side effects of therapy and when to call my care team

Notes:



Treatment: CAR T-cell therapy

Notes:



Possible side effects of therapy and when to call my care team

Notes:



Treatment: BsAbs

Notes:



Possible side effects of therapy and when to call my care team

Notes:



Treatment: ADCs

Notes:



Possible side effects of therapy and when to call my care team

Notes:



Contact information (where HCP team can be contacted)

Notes:



- ☐ Am I eligible for clinical trial participation?
- ☐ Are there any clinical trials near me that you would recommend? How do I sign up?

Available Patient Resources

Disease Information and Clinical Guidelines
[NCCN.org](#)

Advocacy and Patient Support
[SmartPatients](#)

Copays and Other Financial Assistance
[Leukemia/Lymphoma Society](#)

Notes:



References

1. seer.cancer.gov/statfacts/html/dlbcl.html
2. Mamgain. J Family Med Prim Care. 2022;11:4151.
3. Yao. Leukemia. 2018;32:353.

4. Al-Mansour. Asian Pac J Cancer Prev. 2023;24:623.
5. Vodicka. ASH 2023. Abstr 3140.
6. NCCN. Clinical practice guidelines in oncology. B-cell lymphomas. v3.2025. nccn.org.